SCHEMBL4907254

SCHEMBL4907254

N#Cc1c(-c2cccc(Cl)c2)nc(NC2CC2)[nH]c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 5/20 0.49
ADORA2A P29274 5/20 0.49
ADORA2B P29275 2/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 3/20 0.45
ALDH1A1 P00352 3/20 0.45
HTT P42858 2/20 0.45
KDM4E B2RXH2 2/20 0.45
LMNA P02545 1/20 0.45
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45
IDO1 P14902 1/20 0.44
TDO2 P48775 1/20 0.44
LDHA P00338 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
TRPA1 O75762 1/20 0.43
BRD4 O60885 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4906948 0.88 ADORA1 (0.46) ADORA1ADORA2AADORA2BMEN1KMT2A
SCHEMBL4905878 0.86 LMNA (0.56) MEN1KMT2APOLBHPGDALDH1A1
SCHEMBL4899405 0.84 CYP11B1 (0.43) MEN1KMT2APOLBHPGDALDH1A1
SCHEMBL4898075 0.83 BRD4 (0.44) MEN1KMT2AHPGDALDH1A1HTT
SCHEMBL4903905 0.83 BRD4 (0.48) ADORA1ADORA2AMEN1KMT2AHPGD
SCHEMBL4904199 0.81 HPGD (0.47) ADORA1ADORA2AADORA2BMEN1KMT2A
SCHEMBL4908557 0.81 ADORA2A (0.46) ADORA1ADORA2AADORA2BMEN1KMT2A
SCHEMBL4898304 0.80 ALDH1A1 (0.42) MEN1KMT2APOLBHPGDALDH1A1
SCHEMBL4907452 0.79 MEN1 (0.53) ADORA1ADORA2BMEN1KMT2APOLB
SCHEMBL4906447 0.78 BRD4 (0.55) MEN1KMT2APOLBHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ADORA1 529/4885ADORA2A 837/4885ADORA2B 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.